The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Subscribe To Our Newsletter & Stay Updated
